טוען...
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
BACKGROUND: Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite aggressive multimodal therapy. ATC has a high prevalence of BRAF(V600E) mutations and is associated with an immunosuppressive microenvironment; we previously demonstrated that the combination of BRAF i...
שמור ב:
| הוצא לאור ב: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6251038/ https://ncbi.nlm.nih.gov/pubmed/30327563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0296-2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|